GEN Exclusives

More »

GEN News Highlights

More »
Jul 30, 2008

Marshall Edwards Pockets $10M in Public Offering

  • Marshall Edwards secured $10 million through a securities subscription agreement with Novogen and OppenheimerFunds. Novogen, which is the parent company, in turn raised A$5.50 million, or $5.18 million, in an equity issue to take part in Marshall Edwards’ financing.

    El Coronado Holdings, which is already a Novogen shareholder, paid A$1.22 per Novogen share. Following this placement El Coronado will hold 19.9% of Novogen's issued stock.

    Marshall Edwards sold 2,908,295 shares to Novogen and 1,700,000 shares to Oppenheimer for $2.17 per share. The firm is focusing on the development of anticancer therapeutics derived from a flavonoid platform. Its lead investigational drug, phenoxodiol, is in a Phase III multinational trial for patients with recurrent ovarian cancer.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?